Loading the company…
Loading the company…
Families: Aneurysm & intracranial embolization.
All companies · Product and company coverage
In the last ten years FDA made 1 decision for Kaneka Medical America (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2021 (1). The latest was on 2021-03-26.
| Family | Decisions on record |
|---|---|
| Aneurysm & intracranial embolization | 1 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2021-03-26 | 510(k) | K210638 | i-ED COIL System |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Kaneka Medical America.
In 2025, Kaneka Medical America reported engagement with 73 surgeons and other clinicians in the states MedaRep covers, worth $314K in consulting, speaking, meals and travel for its device products, the most in Kansas ($73K to 1). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Kansas ($73K, 1 engaged), Pennsylvania ($61K, 5 engaged), Florida ($35K, 5 engaged), New York ($33K, 4 engaged), Massachusetts ($25K, 2 engaged).